[发明专利]一种基于组学数据的药物再利用方法

权利要求书

1.一种药物再利用的方法， 其特征是：结合临床分析的全基因组关联、蛋白质组学和代谢组学数据，筛选出人类糖尿病相关风险蛋白质，利用药物开发数据库，糖尿病发病机制和药物作用模式，挖掘出具有治疗人类糖尿病效果的药物。

2.根据权利要求1所述的方法，其特征是通过分析全基因组关联分析数据，挖掘人类糖尿病风险基因和蛋白质。

3.根据权利要求1所述的方法，其特征是通过蛋白质组学分析数据，挖掘人类糖尿病相关蛋白质。

4.根据权利要求1所述的方法，其特征是通过代谢组学分析数据，挖掘人类糖尿病相关代谢物，并根据人类代谢物数据库（the Human Metabolome Database, HMDB）寻找这些代谢物的相关蛋白质, 构建人类糖尿病相关代谢物－蛋白质网络图。

5.根据权利要求1所述的方法，其特征是利用药物开发数据库（Therapeutic Target Database, TTD），筛选出已经上市或者处于临床实验阶段的药物，其药物靶点是针对具有人类糖尿病相关风险的蛋白质。

6.根据权利要求1所述的方法， 其特征是利用OMIM和PubMED数据库发掘糖尿病发病机理，比如获得功能型（gain of function, GOF），或失去功能型（loss of function, LOF）。

7.根据权利要求1所述的方法，其特征是利用TTD数据库发掘药物作用模式，比如抑制作用，或激活作用。

8.一种治疗人类糖尿病的方法，其特征是利用以下表格所列一个或多个药物治疗人类糖尿病，

表1：

Drug nameTargetAction modePathogenesis^#PhenoxybenzamineAlpha-2A adrenergic receptor    antagonistLOF, rescue insulin secretion in congenic isletsIdazoxanAlpha-2A adrenergic receptor    antagonistLOF, rescue insulin secretion in congenic isletsClobetasolPhospholipase A2inhibitorGOF, deleterious to normal beta-cell secretory functionDesonidePhospholipase A2inhibitorGOF, deleterious to normal beta-cell secretory functionDesoximetasonePhospholipase A2inhibitorGOF, deleterious to normal beta-cell secretory functionDiflorasonePhospholipase A2inhibitorGOF, deleterious to normal beta-cell secretory functionHalobetasol PropionatePhospholipase A2inhibitorGOF, deleterious to normal beta-cell secretory functionHydrocortamatePhospholipase A2inhibitorGOF, deleterious to normal beta-cell secretory functionQuinacrinePhospholipase A2inhibitorGOF, deleterious to normal beta-cell secretory functionMiltefosinePhospholipase A2inhibitorGOF, deleterious to normal beta-cell secretory functionVarespladibPhospholipase A2inhibitorGOF, deleterious to normal beta-cell secretory functionEchothiophate IodideCholinesterase    inhibitorLOF, potentiate insulin actionHexafluronium bromideCholinesterase    inhibitorLOF, potentiate insulin actionHydrocortisoneNitric oxide synthase, inducible    inhibitorGOF, impair beta-cell function; LOF, reversed fasting hyperglycemiacarprofenProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMCelecoxibProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMDiflunisalProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMEtodolacProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMEtoricoxibProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMIbuprofenProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMKetoprofenProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMLumiracoxibProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMMefenamic acidProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMMeloxicamProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMNabumetoneProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMNaproxenProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMNiflumic AcidProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMPhenylbutazoneProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMPiroxicamProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMTenoxicamProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMTiaprofenic acidProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMTolmetinProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMValdecoxibProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMONO-2506Prostaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMCelecoxibProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMGSK-644784Prostaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMGW-406381Prostaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMRofecoxibProstaglandin G/H synthase 2inhibitorLOF, increase insulin secretion; GOF, IDDMD-cycloserineNMDA receptoragonistGOF, lower glucose productionD-cycloserineNMDA receptoragonistGOF, lower glucose productionD-serineNMDA receptoragonistGOF, lower glucose productionRemacemideNMDA receptoragonistGOF, lower glucose productionRemacemideNMDA receptoragonistGOF, lower glucose productionBuspironeSerotonin-1AagonistLOF, impair insulin secretionFlibanserinSerotonin-1AagonistLOF, impair insulin secretionMN-305Serotonin-1AagonistLOF, impair insulin secretionOPC-14523Serotonin-1AagonistLOF, impair insulin secretionTGBA01ADSerotonin-1AagonistLOF, impair insulin secretionOPC-14523Serotonin-1AagonistLOF, impair insulin secretion1192U90Serotonin-1AagonistLOF, impair insulin secretionAdatanserinSerotonin-1AagonistLOF, impair insulin secretionBifeprunoxSerotonin-1AagonistLOF, impair insulin secretionPRX-00023Serotonin-1AagonistLOF, impair insulin secretionSLV-313Serotonin-1AagonistLOF, impair insulin secretionSarizotanSerotonin-1AagonistLOF, impair insulin secretionPerhexilineCarnitine O-palmitoyltransferase IinhibitorLOF, decrease glucose productionand reduce insulin resistanceCisapride5-hydroxytryptamine 4 receptoragonistGOF, improve insulin sensitivityMedusa IL-2Interleukin-2 receptor subunit betaagonistGOF, reverse/prevent diabetesSotrastaurin acetateProtein kinase C, theta typeinhibitorLOF, prevent insulin resistanceRamelteonMelatonin receptor type 1BagnoistLOF, type 2 diabetes

#Pathogenesis information were retrieved from OMIM or Pubmed database。